TABLE A1.
Treatment at First Recurrence in Patients With Chemotherapy-Resistant Bladder Cancer (n = 102)
| Line of Therapy | Category | Drug | n |
|---|---|---|---|
| 1 | Chemotherapy (n = 44) | Pemetrexed | 10 |
| Paclitaxel | 13 | ||
| Gemcitabine/carboplatin | 5 | ||
| Docetaxel | 2 | ||
| Ifosfamide/paclitaxel/cisplatin | 2 | ||
| MVAC | 2 | ||
| 5-FU/MMC with radiotherapy | 1 | ||
| Carboplatln | 1 | ||
| Carboplatin/etoposide | 1 | ||
| Carboplatin/paclitaxel | l | ||
| Cisplatin/gemcitabine | 1 | ||
| Cisplatin/gemcitabine/docetaxel | 1 | ||
| Docetaxel/ramicirumab | 1 | ||
| Gemcitabine | 1 | ||
| Paclitaxel/carboplatin/bevacizumab | 1 | ||
| Pemetrexed/docetaxel | 1 | ||
| 1 | Immunotherapy (n = 32) | Pembrolizumab | 18 |
| Atezolizumab | 8 | ||
| Nivolumab | 4 | ||
| Ipilimumab/nivolumab | 2 | ||
| 1 | Targeted therapy (n = 5) | Sunitinib | 1 |
| Everolimus | 1 | ||
| Buparlisib | 1 | ||
| Rucaparib | 1 | ||
| Clinical trial | 1 | ||
| 1 | Unknown (n = 1) | Treatment at outside facility | 1 |
| 1 | Palliative care (n = 20) | ||
| 2 | Chemotherapy (n = 10) | Paclitaxel | 5 |
| Docetaxel | 2 | ||
| Pemetrexed | 2 | ||
| Cisplatin | 1 | ||
| 5-FU/leucovorin | 1 | ||
| 2 | Immunotherapy (n = 8) | Atezolizumab | 7 |
| Ipilumumab/nivolumab | 2 | ||
| Pembrolizumab | 1 | ||
| Nivolumab/cabozantinib | 1 | ||
| 2 | Targeted therapy (n = 4) | Enfortumab vedotin | 2 |
| Erdafitinib | 1 | ||
| Infigratinib | 1 | ||
| Sunitinib | 1 | ||
| 3 | Chemotherapy (n = 2) | Carboplatin/paclitaxel | 1 |
| 5-FU/leucovorin | 1 | ||
| 3 | Targeted therapy (n = 1) | Mocetinostat | 1 |
Abbreviations: 5-FU, 5-fluorouracil; MMC, mitomycin C; MVAC, methotrexate, vinblastine, adriamycin, cisplastin.